Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms.
Teva Pharmaceutical Industries
Breaking News
- Investor Dan Calugar Discusses Whether the Emergence of Quantum Computing in Algorithmic Trading Is a Game-Changer for Financial Markets
- Meet Grant Conner: The Eco-Friendly Gold Supplier Revolutionizing the Jewelry Industry
- MBD Financials: The Revolutionary Platform Redefining How We Harness the Digital Age to Empower Others
Israel's Teva Pharmaceutical Industries said it would buy U.S. neurology drug company Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.
The single largest stock holding of Soros Fund Management in the fourth quarter is Israeli drugmaker Teva Pharmaceutical Industries Ltd, Reuters reported citing a February 14 filing with the US Securities and Exchange Commission.
The world's largest generic drugmaker, Teva Pharmaceutical Industries Ltd, has chosen Erez Vigodman to become its President and Chief Executive Officer beginning February 11, Bloomberg reported.
TheMarker, a financial news website, said generic drugmaker Teva Pharmaceutical Industries is set to name Erez Vigodman as its new Chief Executive on January 13 at the JPMorgan Healthcare Conference in San Francisco, Reuters reported.
CEO Jeremy Levin resigns from Teva, but board is confident they will find a permanent replacement.
Subscribe to VCpost newsletter
Most Popular
